Decoy Therapeutics announced a multi-part financing package centered on a $3.5 million private placement at $5.91 per share with an institutional investor, including pre-funded warrants and milestone-based Series A, B, and C warrants that could add up to approximately $17.5 million in additional proceeds upon cash exercise after stockholder approval and milestone achievement. The company also granted resale registration rights to the investor, engaged Curvature Securities as sole placement agent with a 9% fee and a 6% placement agent warrant, and secured 90-day lock-ups from executives and directors. Proceeds will support general corporate purposes, including advancing the lead asset into clinical trials.
Agreement 1: Decoy Therapeutics Raises $3.5 Million in Private Placement at $5.91, Adds Milestone Warrants
- Agreement type: Securities Purchase Agreement for private placement of equity and milestone warrants
- Counterparty: Institutional and accredited investor
- Signed / Effective: Jun 26 2026 / Jun 29 2026
- Duration / Termination: At will
- Reason: Raise capital to advance lead asset into clinical trials
Agreement 2: Decoy Therapeutics Grants Resale Registration Rights to Investor With Liquidated Damages Safeguards
- Agreement type: Registration Rights Agreement for resale of securities
- Counterparty: Institutional and accredited investor
- Signed / Effective: Jun 26 2026 / Jun 26 2026
- Duration / Termination: At will
- Reason: Provide resale liquidity and support investor participation
Agreement 3: Decoy Therapeutics Engages Curvature Securities; Pays 9% Fee, Issues 6% Warrant for Placement
- Agreement type: Placement Agency Agreement for private placement
- Counterparty: Curvature Securities
- Signed / Effective: Jun 26 2026 / Jun 26 2026
- Duration / Termination: At will
- Reason: Execute and distribute the private placement
Agreement 4: Decoy Therapeutics Directors and Officers Sign 90-Day Lock-Up Backing Financing
- Agreement type: Lock-Up Agreements by executive officers and directors
- Counterparty: Curvature Securities
- Signed / Effective: Jun 26 2026 / Jun 29 2026
- Duration / Termination: 90 days after Closing
- Reason: Support orderly trading post-offering
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.